Available Technologies

Oncolytic Activity Using Existing OV Stocks

The current timeframe required for current Good Manufacturing Product (cGMP) validation and approval is significant. The delay between development and approval is time intensive and the advancements that can improve treatment can be outdated by the time they reach the market. Genetic modifications would lead to restarting the production and approval process and delaying the introduction of the entry into human trials. Dr. Kevin Cassady and his team found that combinations of oncolytic viruses (OV) can be combined using current, approved cGMP stocks can be employed effectively and subsequently saving time that would have been spent on re-engineering, production, and validation, as well as the expense associated. The clinical outcome would be improved as this new process allows for a more rapid and cost-effective approach to clinical translation using existing stock of virus.

Tech ID

2020-085

College

(None)

Licensing Manager

Corris, Andrew
Andrew.Corris@nationwidechildrens.org
614-355-1604

Inventors

Categories

External Links

Loading icon